Opinion

Video

Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.

Video content above is prompted by the following questions:

  1. Discuss the data that was presented at the ASCO 2024 on overall survival from the CheckMate 9LA study with the use of nivolumab + ipilimumab + chemotherapy in patients with metastatic NSCLC.
  2. What are your key takeaways from this study?
  3. How do you think the long term follow up data supports decision-making in metastatic NSCLC?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Jorge J. Nieva, MD, Keck School of Medicine
5 experts in this video
5 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo